Lipid-lowering therapy in patients with peripheral arterial disease: Are guidelines being met?

被引:4
作者
Federman, DG
Ranani, DC
Kirsner, RS
Bravata, DM
机构
[1] W Haven Vet Affairs Med Ctr, Dept Internal Med, West Haven, CT USA
[2] Clin Epidemiol Res Ctr, West Haven, CT USA
[3] Miami Vet Affairs Med Ctr, Dept Dermatol, Miami, FL USA
关键词
D O I
10.4065/80.4.494
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: To determine the proportion of patients with lower extremity peripheral arterial disease (PAD) who reach recommended low-density lipoprotein cholesterol (LDL-C) levels (< 100 mg/dL) and to identify the patient characteristics that are independently associated with attaining the LDL-C goal (< 100 mg/dL). PATIENTS AND METHODS: Eligible patients were identified from a roster of patients who had undergone testing at a nonvascular laboratory between September 1, 2001, and January 31, 2002, and were found to have evidence of PAD, defined as an ankle-brachial index of 0.9 or less. We thoroughly reviewed patients' electronic medical records. Backward elimination multivariate logistic regression modeling was used to identify factors associated with reaching the goal LDL-C level. RESULTS: Among 143 patients with PAD, 105 (73%) met the goal LDL-C level. Lipid-lowering therapy was prescribed for 109 (76%). Lower diastolic blood pressure and lower weight were independently associated with an LDL-C level of less than 100 mg/dL. CONCLUSION: We found higher rates of lipid-lowering therapy in patients with PAD than reported previously. Patients with diabetes mellitus or coronary artery disease were not more likely to meet the goal LDL-C level than those without these comorbidities. Clinical practice may be catching up to clinical guidelines.
引用
收藏
页码:494 / 498
页数:5
相关论文
共 21 条
[1]  
Anand SS, 1999, CAN J CARDIOL, V15, P1259
[2]   EFFECTS OF COLESTIPOL-NIACIN THERAPY ON HUMAN FEMORAL ATHEROSCLEROSIS [J].
BLANKENHORN, DH ;
AZEN, SP ;
CRAWFORD, DW ;
NESSIM, SA ;
SANMARCO, ME ;
SELZER, RH ;
SHIRCORE, AM ;
WICKHAM, EC .
CIRCULATION, 1991, 83 (02) :438-447
[3]   Cholesterol in peripheral vascular disease - a suitable case for treatment? [J].
Clark, AL ;
Byrne, JC ;
Nasser, A ;
McGroarty, E ;
Kennedy, JA .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1999, 92 (04) :219-222
[4]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[5]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[6]   Importance of events per independent variable in proportional hazards analysis .1. Background, goals, and general strategy [J].
Concato, J ;
Peduzzi, P ;
Holford, TR ;
Feinstein, AR .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (12) :1495-1501
[7]   THE PREVALENCE OF PERIPHERAL ARTERIAL-DISEASE IN A DEFINED POPULATION [J].
CRIQUI, MH ;
FRONEK, A ;
BARRETTCONNOR, E ;
KLAUBER, MR ;
GABRIEL, S ;
GOODMAN, D .
CIRCULATION, 1985, 71 (03) :510-515
[8]   MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE [J].
CRIQUI, MH ;
LANGER, RD ;
FRONEK, A ;
FEIGELSON, HS ;
KLAUBER, MR ;
MCCANN, TJ ;
BROWNER, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (06) :381-386
[9]  
Dormandy J, 1999, Semin Vasc Surg, V12, P142
[10]   Epidemiology of peripheral vascular disease [J].
Fowkes, FGR .
ATHEROSCLEROSIS, 1997, 131 :S29-S31